EMRA TECHNOLOGIES

A very specific kind of brain cell dies off in people with Parkinson’s

     Support nonprofit journalism.
     Certain human brain cells selectively die off in Parkinson’s disease.  Among cells that produce the chemical messenger dopamine (green), an active
      gene (labeled in magenta) sets these vulnerable cells apart.
     Macosko Lab
     By
     Deep in the human brain, a very specific kind of cell dies during Parkinson’s disease.
     For the first time, researchers have sorted large numbers of human brain cells in the substantia nigra into 10 distinct types. Just one is especially vulnerable in Parkinson’s disease, the team reports May 5 in
     . The result could lead to a clearer view of
     , and perhaps even ways to stop it.
     The new research “goes right to the core of the matter,” says neuroscientist Raj Awatramani of Northwestern University Feinberg School of Medicine in Chicago. Pinpointing the brain cells that seem to be especially susceptible to the devastating disease is “the strength of this paper,” says Awatramani, who was not involved in the study.
     Parkinson’s disease steals people’s ability to move smoothly, leaving balance problems, tremors and rigidity. In the United States, nearly 1 million people are estimated to have Parkinson’s.  Scientists have known for decades that these symptoms come with the death of nerve cells in the substantia nigra.
      churn out dopamine, a chemical signal involved in movement, among other jobs (
     ).
     But those dopamine-making neurons are not all equally vulnerable in Parkinson’s, it turns out.
     “This seemed like an opportunity to … really clarify which kinds of cells are actually dying in Parkinson’s disease,” says Evan Macosko, a psychiatrist and neuroscientist at Massachusetts General Hospital in Boston and the Broad Institute of MIT and Harvard.
     Headlines and summaries of the latest
      articles, delivered to your inbox
     Thank you for signing up!
     There was a problem signing you up.
     The tricky part was that dopamine-making neurons in the substantia nigra are rare. In samples of postmortem brains, “we couldn’t survey enough of [the cells] to really get an answer,” Macosko says. But Abdulraouf Abdulraouf, a researcher in Macosko’s laboratory, led experiments that sorted these cells, figuring out a way to selectively pull the cells’ nuclei out from the rest of the cells present in the substantia nigra. That enrichment ultimately led to an abundance of nuclei to analyze.
     By studying over 15,000 nuclei from the brains of eight formerly healthy people, the researchers further sorted dopamine-making cells in the substantia nigra into 10 distinct groups. Each of these cell groups was defined by a specific brain location and certain combinations of genes that were active.
     When the researchers looked at substantia nigra neurons in the brains of people who died with either Parkinson’s disease or the related Lewy body dementia, the team noticed something curious: One of these 10 cell types was drastically diminished.
     These missing neurons were identified by their location in the lower part of the substantia nigra and an active
      gene, lab member Tushar Kamath and colleagues found. That gene was thought to serve simply as a good way to identify these cells, Macosko says; researchers don’t know whether the gene has a role in these dopamine-making cells’ fate in people.
     The new finding points to ways to perhaps counter the debilitating diseases. Scientists have been keen to replace the missing dopamine-making neurons in the brains of people with Parkinson’s. The new study shows what those cells would need to look like, Awatramani says. “If a particular subtype is more vulnerable in Parkinson’s disease, maybe that’s the one we should be trying to replace,” he says.
     In fact, Macosko says that stem cell scientists have already been in contact, eager to make these specific cells. “We hope this is a guidepost,” Macosko says.
     The new study involved only a small number of human brains. Going forward, Macosko and his colleagues hope to study more brains, and more parts of those brains. “We were able to get some pretty interesting insights with a relatively small number of people,” he says. “When we get to larger numbers of people with other kinds of diseases, I think we’re going to learn a lot.”
     Questions or comments on this article? E-mail us at 
     T. Kamath et al.
     .
     . Published online May 5, 2022. doi: 10.1038/s41593-022-01061-1.
     Laura Sanders is the neuroscience writer. She holds a Ph.D. in molecular biology from the University of Southern California.
      was founded in 1921 as an independent, nonprofit source of accurate information on the latest news of science, medicine and technology. Today, our mission remains the same: to empower people to evaluate the news and the world around them. It is published by the Society for Science, a nonprofit 501(c)(3) membership organization dedicated to public engagement in scientific research and education.
      © Society for Science & the Public 2000–2022. All rights reserved.
     Subscribers, enter your e-mail address for full access to the
      archives and digital editions.
     Not a subscriber?
     
     .
May 05th, 2022
source